Member Info for B2HS2L

https://novacyt.com/wp-content/uploads/2022/09/Investor-Presentation-September-2022_FINAL.pdf

johnny19 -
B2, you're looking at the green shoots in the front garden as your house burns down behind you.

I was sick of viewing the embers johnny, - that's when I noticed the shoots.

I would like to know what the Clonit deal might be worth. - We have the ability to distribute no question.

ash in the bank?
Loving it :o)

What's not mentioned is the Bioinformatics team and it's automated operation.
Significant asset, providing a market lead in terms of new assay gestation period.
Definitely market disruptive.

HC - Bullsh*t alert. - Don't get dragged in.

BYP - are you 100% out?

Green Shoots!

"Post-period highlights
• Significantly expanded the clinical portfolio, adding 40 CE IVD assays, through a
distribution agreement with Clonit srl, an Italian-based molecular diagnostic
developer and manufacturer, to drive near-term growth
• Re-launched RUO portfolio globally with initial orders of over £100k in aggregate,
including testing infectious salmon anaemia virus and bacterial kidney disease in
salmon in Canada and testing salmonella in chickens in Poland, with the expectation
of repeat business "

Willing to discuss small orders? - Unlike NCYT?

The company are only 79 pence per share away from worthless.
We've absorbed most of the pain of the plummeting sp, so selling out now doesn't make much sense.
If there is a presentation tomorrow, how much bad news can it contain. Most of the bad news is out there IMO.

Thanks for that link and the jigsaw piece EXMEX.
Sounds potentially lucrative.
Will be hearing much more about it tomorrow I'm sure.

If a discussion includes the term 'viral panels', I assume that means a PCR based test.
I don't think I have come across that term when LFT's are discussed.

source: https://www.linkedin.com/in/murali-painter-aa5ba7119/

Novacyt Business Development Manager
Jul 2021 - Jan 2022 · 7 mos
- Customer acquisition within the private testing market across the UK and Ireland including DAM HEALTH.
- Key Account Management of our relationships with AstraZeneca, TAC Healthcare, SYNLAB UK.
- Account Management of numerous private testing labs in the UK.

++++

EXMEX - Does this tend to confirm your theory? - If not what else do you seek?

We don't know if that means the presentation goes on the website at 07:00 or 08:00 or beginning of presentation.

'We are looking for someone to be responsible for the management of operational quality assurance relating to the manufacture, packing and distribution of Investigational Medicinal Products for use in Synairgen clinical trials, and for supporting the development, qualification and compliance of a commercial product supply chain thereafter.'
+++

Just read this thread.
I didn't read that the successful candidate might take as long as 3 months to extricate themselves from their present position.
It doesn't answer why we know about this vacancy this week rather than next,
but I rather think 3 months is the length of time they expect to wait for these services.

ie somebody won't be responsible next week, for the management of operational quality assurance relating to the manufacture, packing and distribution of Investigational Medicinal Products .

Your former comment was 'We know the Bod don’t give a hoot about investors'.
I'll go with that all day long crl123.

Courtesy poster Feef56 on SNG:
https://fortune.com/well/2022/09/24/new-covid-omicron-variants-subvariants-evade-monoclonal-antibodies-bebtelovimab-recombinants-convergent-evolution-sars-immune-evasion/

'Rajnarayanan worries for the future of COVID countermeasures and, like WHO officials, calls on countries to keep up testing and the genetic sequencing of samples. It’s the only way to know what’s coming, they contend. Ideally, such knowledge will allow researchers to scramble to create new countermeasures, or update old ones, as necessary.'

“We used to say we have the tools,” he said. “The tools are getting picked off.”

This article identifies some of the latest variants, and we can only hope their ability to evade vaccines and natural immunity is not as good as we fear.
However our automated Bioinformatics team will be ideally placed to lead R&D staff in their efforts to create new tests as first responders if necessary.

Testing and still has a part this winter.

"This normally means they have finished their quick profit and are bringing it down again to where it was. Shoot me yes, "but I can see miserable seventies as they buy up again tomorrow."

"A poor one [CEO] is uninterested and just going through the motions on a basic salary. I suspect we have the latter , but on a nice fat lazy salary."

crl123 - Why would they buy in again tomorrow, when there is a presentation Q/A opportunity on Thursday, and as YOU say, bad news likely. Surely that's too risky?

It was a pump / dump opportunity on a share way under valued.
I'd be staying out in theses circumstances.
But I also might be buying with half of yesterdays profit on the dip tomorrow, in case I was wrong.
JM2c

https://www.linkedin.com/jobs/search/?alertAction=viewjobs¤tJobId=3247429087&f_C=10894668&f_TPR=a1663566230-&savedSearchId=1725771770&searchAlertRefId=7fcd9f14-d045-47ed-af27-6d2546870b36

These are the new positions and the number of applicants. I'm hoping that they are not just replacements for staff who have moved on. If they are new jobs, then we are likely to be selling more products.

HC, -
I'd settle for evidence the new products are being sold in quantity, validating all the hard work defining what the new products should be.
Then we would know DA's reputation for marketing magic was becoming evident.

When I experience this problem I change the 'Posts per page' setting.
That sometimes works.

PI100 - Surprised and delighted as all other genuine Holders.

You are not fooling anybody. - You want your cake and eat it.

I do hope the sp allows you to leave this board soonest.